FindTrial
Sign In

Nafamostat Mesylate

DRUG8 trials

Sponsors

Gyeongsang National University Hospital, Ensysce Biosciences, Xiaobo Yang, MD, Wonju Severance Christian Hospital, Shen Lei

Conditions

Acute Kidney InjuryAnticoagulationBleedingCOVID-19Continuous Renal Replacement Therapy (CRRT)Corona Virus InfectionCritical IllnessDialysis; Complications

Phase 1

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)
CompletedNCT05090280
Ensysce BiosciencesPharmacokinetics
Start: 2021-12-01End: 2023-04-26Updated: 2024-09-24
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RecruitingNCT06500793
Ensysce BiosciencesPharmacokinetics
Start: 2024-11-24End: 2026-12-31Target: 30Updated: 2026-03-06

Phase 2

Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia
NCT04418128
Gyeongsang National University HospitalCorona Virus Infection, COVID-19
Start: 2020-06-10End: 2021-04-30Target: 84Updated: 2020-06-09
Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation
NCT05555641
Xiaobo Yang, MDAnticoagulation, Critical Illness
Start: 2022-12-20End: 2024-10-01Target: 40Updated: 2023-02-15

Phase 4

Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI
Not yet recruitingNCT06375616
Shen LeiSepsis
Start: 2024-04-30End: 2027-04-30Target: 156Updated: 2024-04-19
Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury
Not yet recruitingNCT07518303
Jianfeng XieAcute Kidney Injury, Continuous Renal Replacement Therapy (CRRT), Sepsis
Start: 2026-04-01End: 2028-06-01Target: 1162Updated: 2026-04-08

Unknown Phase

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study
RecruitingNCT05874674
Wonju Severance Christian HospitalBleeding, Dialysis; Complications
Start: 2023-12-01End: 2026-12-31Target: 100Updated: 2024-07-30
The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration
Not yet recruitingNCT06994312
The First Hospital of Jilin UniversitySepsis-induced Coagulopathy (SIC)
Start: 2025-07-01End: 2028-12-01Target: 282Updated: 2025-05-29

Related Papers

Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial.
2021-11-238 citations